Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) EBIT Margin: 2020-2025

Historic EBIT Margin for Silence Therapeutics (SLN) over the last 6 years, with Sep 2025 value amounting to 16,505.66%.

  • Silence Therapeutics' EBIT Margin fell 1450319.00% to 16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 321.21%, marking a year-over-year increase of 11438.00%. This contributed to the annual value of 146.38% for FY2024, which is 5709.00% up from last year.
  • Latest data reveals that Silence Therapeutics reported EBIT Margin of 16,505.66% as of Q3 2025, which was down 54.29% from 10,697.77% recorded in Q2 2025.
  • Silence Therapeutics' EBIT Margin's 5-year high stood at 17.20% during Q4 2024, with a 5-year trough of 20,006.34% in Q1 2025.
  • Its 3-year average for EBIT Margin is 4,864.42%, with a median of 633.59% in 2023.
  • As far as peak fluctuations go, Silence Therapeutics' EBIT Margin skyrocketed by 61,639bps in 2024, and later crashed by 1,997,079bps in 2025.
  • MRQ analysis of 5 years shows Silence Therapeutics' EBIT Margin stood at 329.91% in 2021, then soared by 30bps to 230.03% in 2022, then crashed by 175bps to 633.59% in 2023, then skyrocketed by 97bps to 17.20% in 2024, then crashed by 95,873bps to 16,505.66% in 2025.
  • Its EBIT Margin stands at 16,505.66% for Q3 2025, versus 10,697.77% for Q2 2025 and 20,006.34% for Q1 2025.